Timmy Cheng, MD
Critical Care Medicine · Orange, CANPI 1295078764
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,000 of the $16,488 with a category attached, or 72.8%. Intuitive Surgical accounts for 78.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $13,394 and has fallen 92.1% since, to $1,064 in 2025. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $171.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$300
- Philips North America LLC$225
- Sanofi$224
- Boehringer Ingelheim$147
- plus $550 from 10 others
Across 158 payments — averaging $1419.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$224K
What the payments were for
- Travel & lodging$9616%
- Food & beverage$3,52721%
- Education$12,00073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $12,977 |
| GSK | 43 | $2,065 |
| Actelion Pharmaceuticals US, Inc. | 20 | $300 |
| Philips North America LLC | 5 | $225 |
| Sanofi | 3 | $224 |
| Boehringer Ingelheim | 2 | $147 |
| Sun Pharmaceutical Industries Inc. | 1 | $124 |
| Dompe US, Inc. | 1 | $98 |
| Genentech USA, Inc. | 2 | $90 |
| Verona Pharma, Inc. | 2 | $65 |
| Genentech, Inc. | 1 | $46 |
| Liquidia Technologies, Inc. | 1 | $34 |
| Abiomed | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $21 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,488 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $105,774 |
| NucalaMepolizumab | 13 | $47,819 |
| Spiriva RespimatTiotropium Bromide | 37 | $27,769 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $26,360 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $14,683 |
| Spiriva HandihalerTiotropium Bromide | 12 | $14,361 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,492 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $9,716 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,358 |
| EliquisApixaban | 12 | $9,224 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $8,713 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,904 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,509 |
| Advair DiskusFluticasone Propion/Salmeterol | 16 | $5,595 |
| DuleraMometasone/Formoterol | 15 | $5,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $2,065 | $183,426210 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $147 | $51,16572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Orange
- Bassam YaghmourOrange$376K
- Huawei DongOrange$44K
- Shahid HayatOrange$13K
- Lillian ChowOrange$11K
- Amir GhiassiOrange$10K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Xuanha WhiteSan Diego$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.